MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533864 | Name: Moexiprilat hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moexiprilat hydrochloride is a bioactive chemical.

Chemical Structure

Moexiprilat hydrochloride
Moexiprilat hydrochloride
CAS#82586-57-0

Theoretical Analysis

MedKoo Cat#: 533864

Name: Moexiprilat hydrochloride

CAS#: 82586-57-0

Chemical Formula: C25H31ClN2O7

Exact Mass: 506.1820

Molecular Weight: 506.98

Elemental Analysis: C, 59.23; H, 6.16; Cl, 6.99; N, 5.53; O, 22.09

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Moexiprilat hydrochloride
IUPAC/Chemical Name
(3S)-2-((2S)-2-(((1S)-1-(carboxy)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride
InChi Key
ZVLZMESUJYRKKI-ZAFWUOJLSA-N
InChi Code
InChI=1S/C25H30N2O7.ClH/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32;/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32);1H/t15-,19-,20-;/m0./s1
SMILES Code
O=C([C@H]1N(C([C@@H](N[C@H](C(O)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Moexiprilat hydrochloride is a bioactive chemical.
In vitro activity:
In vitro, moexiprilat was a potent inhibitor of ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50 values of 2.6 and 4.9 nmol/l, respectively. Both, moexipril and moexiprilat inhibited the angiotensin I (ANG I)-induced contractions of rabbit aorta concentration-dependently, whereas contractions by other agents were not affected, indicating a high selectivity of both compounds for ACE. Reference: Arzneimittelforschung. 1997 Feb;47(2):132-44. https://pubmed.ncbi.nlm.nih.gov/9079232/
In vivo activity:
The effects of 2-2-(1-(ethoxycarbonyl)-3-phenylpropyl)-[amino-oxopropyl]-6,7-dimethoxy- 1,2,3,4-tetrahydroisoquinoline-3 carboxylic acid (moexiprilat), 17beta-oestradiol (E2), oestrone (ES) and angiotensin II (AII) on growth and activation of oestrogen receptors and the immediate-early gene egr-1 were investigated in neonatal rat cardiac fibroblasts of female and male origin. Moexiprilat (10(-7)M) completely inhibited oestrone-induced cardiac fibroblast growth. The induction of oestrogen receptor and egr-1 protein expression was time-dependent and inhibited by moexiprilat. Reference: Br J Pharmacol. 1997 Aug;121(7):1350-4. https://pubmed.ncbi.nlm.nih.gov/9257913/

Preparing Stock Solutions

The following data is based on the product molecular weight 506.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Pines A, Fisman EZ. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs. 2003;3(5):351-60. doi: 10.2165/00129784-200303050-00006. PMID: 14728069. 2. Friehe H, Ney P. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb;47(2):132-44. PMID: 9079232. 3. Grohé C, Kahlert S, Lóbbert K, van Eickels M, Stimpel M, Vetter H, Neyses L. Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. Br J Pharmacol. 1997 Aug;121(7):1350-4. doi: 10.1038/sj.bjp.0701263. PMID: 9257913; PMCID: PMC1564823. 4. Edling O, Bao G, Feelisch M, Unger T, Gohlke P. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. PMID: 7473177.
In vitro protocol:
1. Pines A, Fisman EZ. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs. 2003;3(5):351-60. doi: 10.2165/00129784-200303050-00006. PMID: 14728069. 2. Friehe H, Ney P. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb;47(2):132-44. PMID: 9079232.
In vivo protocol:
1. Grohé C, Kahlert S, Lóbbert K, van Eickels M, Stimpel M, Vetter H, Neyses L. Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. Br J Pharmacol. 1997 Aug;121(7):1350-4. doi: 10.1038/sj.bjp.0701263. PMID: 9257913; PMCID: PMC1564823. 2. Edling O, Bao G, Feelisch M, Unger T, Gohlke P. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. PMID: 7473177.